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June 9, 2009:2197–200have added to the area under the receiver-operator character-
istic curve for the standard risk factors’ ability to prognosticate.
We think that there has not been and will not be a major
breakthrough in prevention, akin to what has dramatically
occurred in diagnostic testing and intervention, until risk
factors are used not for risk assessment, but to identify treatable
causal factors after risk has more accurately been established by
the level of subclinical atherosclerosis (5).
. To those who raise cost effectiveness concerns related to
widespread screening for subclinical atherosclerosis, reduction
in the cost of calcium scanning to the level of mammography
will make it the most cost-effective modality.
. Finally, in both secondary and primary prevention, there has
been a misplaced focus on simple changes in the treated risk
factors, for example, low-density lipoprotein, rather than on
measures of subclinical atherosclerosis and disease activity and
endothelial function to evaluate the response of the disease,
rather than the risk factors, to treatment.
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o Benefit From Cardiac
esynchronization Therapy in
symptomatic Patients
e congratulate Linde et al. (1) on the meticulously carried out
EVERSE (REsynchronization reVErses Remodeling in Systolic
eft vEntricular dysfunction) trial that addressed the question of
he clinical benefit of cardiac resynchronization therapy (CRT) in
atients with New York Heart Association (NYHA) functional
lass II and I heart failure (1). Unfortunately, the composite
rimary end point as defined per the study protocol was negative.
till, the authors conclude that CRT, in combination with optimal
edical treatment ( defibrillator), reduces the risk for heart
ailure hospitalizations and improves ventricular structure and
unction in NYHA functional class II and I. In our opinion, the pater statement is not supported by the presented data, which
hows no benefit for NYHA functional class I patients (odds ratio:
.87; 95% confidence interval: 0.37 to 2.03) in their subgroup
nalysis (Fig. 4 of Linde et al. [1]).
This disagreement raises the more philosophical question:
hether these subgroup analyses make sense if the primary end
oint is negative—maybe due to a lack of statistical power? It
eems that the well-known players such as wide QRS and low left
entricular ejection fraction are positive predictors for CRT success
ut not NYHA functional class I. Another intriguing finding of
his subgroup analysis is that patients on diuretics did improve,
hereas those not on diuretics did not. However, the use of
iuretics reduced mortality and prevented hospital admissions in
his patient population, which raises the question of whether the
se of diuretics by themselves may have accounted for the
ocumented beneficial effect (clinical composite end point, hospi-
alizations) in the CRT ON group and whether this confounding
ariable was corrected for in the main analysis (2).
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eply
e thank Dr. Osswald and colleagues for their interest in our
aper (1). The REVERSE (REsynchronization reVErses Remod-
ling in Systolic left vEntricular dysfunction) study was designed as
ne population of New York Heart Association (NYHA) func-
ional class I to II heart failure (HF) patients. We agree that the
rimary end point did not reach statistical significance (2), with
6% of patients worsened in the cardiac resynchronization therapy
CRT) ON group and 21% in the CRT OFF group (p  0.10).
he clinical composite response was designed for severe HF
atients and, to our knowledge, has not previously been used in
ildly symptomatic or asymptomatic HF patients (3).
The fact that the primary end point did not reach statistical
ignificance despite substantial improvement in left ventricular
LV) dimensions accompanied by a significantly reduced time to
rst HF related hospitalization might be due to the difference in
tility of this end point or that the observation period was not long
nough to demonstrate effects in NYHA functional class I to II
atients. Dr. Osswald and colleagues are concerned about the
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June 9, 2009:2197–200ubgroup analysis in a neutral study and more specifically by the
lack of benefit” in NYHA functional class I patients and in those
ot on diuretics (1). We understand their concern but want to
oint out that subgroup analyses are performed in larger studies to
larify whether a presumed treatment effect can be generalized over
any clinically relevant conditions.
The main finding was an overall positive effect over nearly all
ubgroups, with an odds ratio of 0.70 in favor of CRT. The study
as not powered to show a benefit in NYHA functional class I
atients alone and, therefore, statistical significance for this small
roup of patients should not be expected. Nonetheless, the results
ndeed favor CRT ON in NYHA functional class I patients with
n odds ratio of 0.87. Improvements in left ventricular end-systolic
olume index between NYHA functional class I and II patients
ere substantial in both NYHA functional class I and II groups as
ell as for patients with and without diuretics. Diuretics were not
andomized in any way. The on-diuretics group included both
RT ON and CRT OFF patients, so if “diuretics by themselves
ay have accounted for the documented beneficial effect,” then
oth CRT ON and CRT OFF patients would have shown the
ame improvement. Therefore, this is not a confounding variable.
We thus believe that our conclusion, that CRT reduces the risk
or HF hospitalization and reverses LV remodeling over the course
f 12 months in patients with American College of Cardiology/
merican Heart Association stage C, NYHA functional class I
nd II HF, raising the possibility that CRT might delay disease
rogression in HF patients with mild HF through LV reverse
emodeling, is valid. Because the REVERSE study was not
imensioned as a morbidity/mortality trial we will have to wait for
he ongoing MADIT-CRT (Multicenter Automatic Defibrillator
mplantation Trial with Cardiac Resynchronization Therapy) and
AFT (Resynchronization/defibrillation for Ambulatory heart
ailure Trial) studies and the 24-month REVERSE study results
o obtain the final answer as to whether CRT may modify disease
rogression in mildly symptomatic HF patients (4,5).
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arly Repolarization
n the Athlete
n “abnormal” resting electrocardiogram is common in top-
anking, endurance-trained athletes (1). These abnormalities be-
ong to physiological changes induced by training, as sinus brady-
ardia, high QRS and T-wave voltages, and early repolarization
ER), consisting of an elevation of QRS–ST junction, or a QRS
otching/slurring. Until now, ER has been considered benign (2).
In a previous article (3), we underlined differences between
entricular repolarization anomalies in top-level athletes and those
resent in patients with Brugada syndrome. ER was observed in
9% of athletes, a value largely different from what was recently
bserved by Rosso et al. (4) in a young athletic group (22%).
The difference in ER prevalence between our athletes and those
tudied by Rosso et al. (4) could be that the former were
ompetitive athletes and the Rosso et al. (4) subjects were
oncompetitive. Moreover, in this study, different from the control
roup, the athletic patients were not age-matched with patients
ith idiopathic ventricular fibrillation (IVF) and were younger
range 17 to 19 years vs. 24 to 70 years). So, the difference in the
revalence of J-point elevation in IVF subjects (42%) may be due
ore to the younger age than to athletic conditioning. We
bserved a similar ER prevalence (36%) in our young nonathletic
ontrols (mean age, 25 years) (3).
Recently, it was suggested that, in some cases, ER may not be
enign (4,5). We would like to stress that top-level endurance-trained
thletes represent a peculiar group of subjects in whom ER and some
ther electrocardiogram anomalies are almost the rule. None of our
thletes has suffered from major ventricular arrhythmias from the time
f the study onward (3). In this way, the meaning of ER, in particular,
n left pre-cordial leads, especially when associated with high QRS
nd T-wave voltages, must be considered a complete benign phenom-
non, reversible after a few months of detraining.
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